7498 Results (Page 297 of 300)
Pharmaceuticals Markets Research Reports
Kenya Clinical Nutrition Market Analysis
The Kenya Clinical Nutrition Market was valued at $21.5 Mn in 2023 and is projected to grow at a CAGR of 6.44% from 2023 to 2023, to $33.2 Mn by 2030. The key drivers of this industry are increasing prevalence of chronic diseases and metabolic disorders, aging population, increasing awareness of the importance of nutrition for health, product innovations and technological advancements, government initiatives and rising healthcare expenditure, rising incidence of malnutrition especially in paediatric patients which has contributed to market growth. The industry is primarily dominated by players such as Nutrivea, Healthwise Kenya, Haltons Pharmacy, Mead Johnson & Company, GSK, Unilever among others.
Mexico Cancer Induced Bone Disease Therapeutics Market
Mexico Cancer Induced Bone Disease Therapeutics Market valued at $20 Mn in 2022, projected to reach $31 Mn by 2030 with a 6.05% CAGR. The key drivers of this industry include the increasing incidence of cancer, improved diagnostics and treatment, and expanding treatment options. The industry is primarily dominated by players such as Amgen, Novartis, Pfizer, Roche, Eli Lilly, Genomma, and Bayer among others.
South Africa Clinical Nutrition Market Analysis
The South Africa Clinical Nutrition Market was valued at $199.4 Mn in 2023 and is projected to grow at a CAGR of 6.57% from 2023 to 2023, to $311.2 Mn by 2030. The key drivers of this industry are increasing prevalence of chronic diseases and metabolic disorders, aging population, increasing awareness of the importance of nutrition for health, product innovations and technological advancements, government initiatives and rising healthcare expenditure, rising incidence of malnutrition especially in paediatric patients which has contributed to market growth. The industry is primarily dominated by players such as Herbalife Nutrition, Optimum Nutrition, Abbott Nutrition, Pfizer Inc, Nestle, Mead Johnson & Company, LLC among others.
Japan Cancer Induced Bone Diseases Therapeutics Market
Japan Cancer Induced Bone Disease Therapeutics Market valued at $81 Mn in 2022, projected to reach $132 Mn by 2030 with a 6.3% CAGR. The key drivers of this industry include the increasing cancer incidence, technological advancements, and unmet medical needs. The industry is primarily dominated by players such as Daiichi Sankyo, Bayer, Merck, Chugai, Takeda, Novartis, Amgen, and Eisai among others.
Brazil Congestive Heart Failure Therapeutics Market Analysis
The Brazil Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $258 Mn in 2022 to $436 Mn by 2030, with a CAGR of 6.8% during the forecast period of 2022-2030. An expanding patient base due to rising cardiac disease prevalence, increased healthcare access around the country, and a thriving R&D environment are the key factors driving the market growth in Brazil. The Brazil Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi, Hypera Pharma, Ache Laboratories, EMS Pharma, Neo Quimica, Teuto Brasileiro, etc, among various others.
India Clinical Nutrition Market Analysis
The India Clinical Nutrition Market was valued at $557.8 Mn in 2023 and is projected to grow at a CAGR of 8.34% from 2023 to 2023, to $977.2 Mn by 2030. The key drivers of this industry are increasing prevalence of chronic diseases and metabolic disorders, aging population, increasing awareness of the importance of nutrition for health, product innovations and technological advancements, government initiatives and rising healthcare expenditure, rising incidence of malnutrition especially in paediatric patients which has contributed to market growth. The industry is primarily dominated by players such as Sun Pharmaceuticals, Zydus Wellness, Glenmark Pharmaceuticals, Zeon Lifesciences, Nestle, Mead Johnson & Company, LLC among others.
Brazil Cancer Induced Bone Disease Therapeutics Market
Brazil Cancer Induced Bone Disease Therapeutics Market valued at $33 Mn in 2022, projected to reach $55 Mn by 2030 with a 6.8% CAGR. The key drivers of this industry include the rising incidence of cancer, improved diagnostics and treatment, and the potential for local manufacturing. The industry is primarily dominated by players such as Advaxis, CancerVax, Pfizer, Takeda, Gradalis, Hikma, and Zentalis among others.
Canada Congestive Heart Failure Therapeutics Market Analysis
The Canada Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $0.824 Bn in 2022 to $1.294 Bn by 2030, with a CAGR of 5.8% during the forecast period of 2022-2030. The key drivers of the Canadian congestive Heart Failure Therapeutics Market include the increasing prevalence of risk factors leading to CVS disorders, advancements in medical technology and intervention options, and supportive government schemes and reimbursement strategies. The Canada Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Johnson & Johnson, Apotex, Paladin Labs, Pharmascience, Sandoz, etc, among various others.
France Cancer Induced Bone Disease Therapeutics Market
France Cancer Induced Bone Disease Therapeutics Market valued at $36 Mn in 2022, projected to reach $52 Mn by 2030 with a 4.8% CAGR. The key drivers of this industry include the increasing prevalence of different cancers, unmet medical needs of the population, and supportive government initiatives. The industry is primarily dominated by players such as Amgen, Novartis, Pfizer, Roche, Eli Lilly, Johnson, and Bayer, among others.
China Congestive Heart Failure Therapeutics Market Analysis
The China Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $0.828 Bn in 2022 to $1.455 Bn by 2030, with a CAGR of 7.3% during the forecast period of 2022-2030. The market in China is driven by a confluence of various factors including a rapidly aging population, urbanization-induced lifestyle changes that increase the incidence of cardiovascular risk factors, and ongoing efforts to develop healthcare infrastructure, all of which contribute to increased demand for therapeutics. The China Congestive Heart Failure Therapeutics Market is dominated by key players from various therapeutic segments, including AstraZeneca, Bayer, Novartis, Eli Lilly, Merck, Sanofi, Jiangsu Hengrui Medicine, Shanghai Fosun Pharmaceutical, Shenzhen Chipscreen Biosciences, Guangzhou Kangchao Pharmaceutical, among others.
Egypt Cancer Induced Bone Diseases Therapeutics Market
Egypt Cancer Induced Bone Disease Therapeutics Market valued at $4 Mn in 2022, projected to reach $6 Mn by 2030 with a 7.3% CAGR. The key drivers of this industry include the rising incidence of cancer, expanding treatment options, and improved diagnoses. The industry is primarily dominated by players such as EVA, AstraZeneca, Merck, Eli Lilly, Pharco, Johnson & Johnson, Amgen, and Novartis among others.
Egypt Congestive Heart Failure Therapeutics Market Analysis
The Egypt Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $29 Mn in 2022 to $51 Mn by 2030, with a CAGR of 7.3% during the forecast period of 2022-2030. The primary drivers in Egypt are the increasing incidence of cardiovascular illnesses, increased consciousness, early detection made possible by technological developments in the field, and the revolutionary stage of CHF treatments with ongoing research and development. The Egypt Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, Gilead Sciences, Copad Pharma, EVA Pharma, Pharco, Pharmaceuticals, Tabia Pharmaceuticals, etc, among various others.
France Congestive Heart Failure Therapeutics Market Analysis
The France Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $283 Mn in 2022 to $412 Mn by 2030, with a CAGR of 4.8% during the forecast period of 2022-2030. The key drivers in France include the aging population, contributing to an increased demand for CHF treatments, ongoing advancements in pharmaceutical research leading to innovative therapies, and government initiatives and reimbursement policies supporting accessibility. The France Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, Servier, Amgen, Otsuka Pharmaceuticals, Lexicon Pharmaceuticals, Tenex Therapeutics, etc, among various others.
China Cancer Induced Bone Disease Therapeutics Market
China Cancer Induced Bone Disease Therapeutics Market valued at $105 Mn in 2022, projected to reach $184 Mn by 2030 with a 7.3% CAGR. The key drivers of this industry include the rising incidence of cancers, government initiatives, and untapped market potential. The industry is primarily dominated by players such as Siemen, Hengrui, Shanghai Pharma, Johnson & Johnson, Novartis, and Amgen among others.
Indonesia Congestive Heart Failure Therapeutics Market Analysis
The Indonesia Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $62 Mn in 2022 to $97 Mn by 2030, with a CAGR of 5.8% during the forecast period of 2022-2030. The growth of the Indonesia Congestive Heart Failure Therapeutics Market is driven by the increasing prevalence of cardiovascular conditions among an aging population, government initiatives enhancing accessibility and affordability, and the potential for healthcare infrastructure improvements, particularly in rural areas. The Indonesia Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, Sanofi, AstraZeneca, Bayer, Eli Lilly, Merck, Kalbe Pharma, Kimia Pharma, Pharos, Indopharma, etc., among various others.
Canada Cancer Induced Bone Diseases Therapeutics Market
Canada Cancer Induced Bone Disease Therapeutics Market valued at $104 Mn in 2022, projected to reach $163 Mn by 2030 with a 5.8% CAGR. The key drivers of this industry include rising cancer incidence, increased research and development, and advancements in cancer diagnostics. The industry is primarily dominated by players such as Amgen, Pfizer, Merck, Eli Lilly, Novartis, Bayer, and Johnson & Johnson, among others.
Japan Congestive Heart Failure Therapeutics Market Analysis
The Japan Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $640 Mn in 2022 to $1,044 Mn by 2030, with a CAGR of 6.3% during the forecast period of 2022-2030. The primary driving factors include the growing emphasis on quality of life, technological developments in medicine that provide novel therapeutic approaches, and the rising incidence of heart failure as a result of aging populations and sedentary lifestyles in Japan. The Japan Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, AstraZeneca, Bayer, Merck, Pfizer, Boehringer Ingelheim, Otsuka, Sumitomo Pharma, Eisai, Meiji Seika Pharma, etc, among various others.
Canada Car T-Cell Therapy Market
Canada Car T-Cell Therapy Market valued at $232 Mn in 2022, projected to reach $393 Mn by 2030 with a 6.8% CAGR. The growing occurrence and prevalence of cancer worldwide, driven by factors like population aging, unhealthy lifestyles, and environmental influences, contribute to an expanding pool of patients who may potentially benefit from CAR T-Cell therapy, thereby expanding the market for this treatment. The top pharmaceutical entities presently operating in the market are Gilead Sciences (Kite Pharma), Novartis, Bristol Myers Squibb, Celgene, Johnson & Johnson, Cellectis, Atara Biotherapeutics, Adaptimmune Therapeutics, Poseida Therapeutics and UCAR-T.
Malaysia Congestive Heart Failure Therapeutics Market Analysis
The Malaysia Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $17 Mn in 2022 to $26 Mn by 2030, with a CAGR of 6% during the forecast period of 2022-2030. The market in Malaysia is driven by the escalating incidence due to aging demographics and unhealthy lifestyle choices, supported by proactive government initiatives to enhance healthcare accessibility and affordability, along with the expanding coverage of CHF medications by insurance policies. Malaysia Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, AstraZeneca, Bayer, Abbott, Roche, Merck, DuoPharma, Pharmaniaga, Hovid, Apex Bio, etc., among various others.
US Car T-Cell Therapy Market
US Car T-Cell Therapy Market valued at $1,218 Mn in 2022, projected to reach $1,772 Mn by 2030 with a 4.8% CAGR. The rising global cancer incidence, driven by aging populations, unhealthy lifestyles, and environmental factors, fuels an expanding population eligible for CAR T-Cell therapy, contributing to the growth of its market. Currently, leading pharmaceutical companies in this market include Gilead Sciences, Novartis, Bristol Myers Squibb, Johnson & Johnson, Kite Pharma, Legend Biotech, Celgene, Cellectis, Atara Biotherapeutics, and UCAR-T.
Mexico Congestive Heart Failure Therapeutics Market Analysis
The Mexico Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $155 Mn in 2022 to $247 Mn by 2030, with a CAGR of 6.05% during the forecast period of 2022-2030. The key drivers of the market include the demographic trend of an aging population, lifestyle-related factors contributing to an increased incidence of heart failure, ongoing advancements in pharmaceutical research leading to novel therapies, and the significant impact of government initiatives. The Mexico Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, Pfizer, Roche, Sanofi, PISA, Sanfer, Genomma Lab, etc, among various others.
Mexico Exosome Research Market Analysis
The Mexico Exosome Research Market was valued at $2.5 Mn in 2023 and is projected to grow at a CAGR of 16.25% from 2023 to 2023, to $7.3 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, and increasing advanced applications of exosomes. The industry is primarily dominated by players such as Thermo Fisher Scientific, NanoSomix, NX Pharmagen, Exosome Diagnostics among others.
Vietnam Cardiac Resynchronization Therapy Market
Vietnam Cardiac Resynchronization Therapy Market valued at $24 Mn in 2022, projected to reach $36 Mn by 2030 with a 5.23% CAGR. The notable increase in heart failure cases worldwide, propelled by aging demographics and lifestyle-associated cardiovascular ailments, stands as a pivotal factor fuelling the growth of the Cardiac Resynchronization Therapy (CRT) market. Presently, key players in this market encompass Abbott, Biotronik, Boston Scientific, Medtronic, St. Jude Medical, Sorin Group, Siemens Healthineers, Philips Healthcare, GE Healthcare, and Esaote.
Philippines Congestive Heart Failure Therapeutics Market Analysis
The Philippines Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $23 Mn in 2022 to $37 Mn by 2030, with a CAGR of 6.3% during the forecast period of 2022-2030. The key drivers of the market include the rising prevalence of CHF due to an aging population and increased risk factors, growing awareness and timely diagnosis leading to early intervention, and ongoing advancements in medications. The Philippines Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, AstraZeneca, Bayer, Abbott, Roche, Merck, Unilab, Metro Drug, Pharmaserv, Medichem, etc, among various others.
Philippines Exosome Research Market Analysis
The Philippines Exosome Research Market was valued at $0.4 Mn in 2023 and is projected to grow at a CAGR of 16.5% from 2023 to 2023, to $1.1 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, and increasing advanced applications of exosomes. The industry is primarily dominated by players such as Hologic Inc., Luminex Corporation, Thermo Fisher Scientific, Cell Guidance Systems LLC, and others.